Skip to main content
HR 1703 115th Congress House

Medical Product Communications Act of 2017

Official title: To amend the Federal Food, Drug, and Cosmetic Act with respect to determining the intended use of drugs and devices.

Introduced: June 2, 2017 Introduced by: Griffith, H. Morgan Republican · Virginia See on congress.gov
Health Drug safety, medical device, and laboratory regulationScientific communication
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 24, 2017
Referred to the Subcommittee on Health.
Mar 23, 2017
Referred to the House Committee on Energy and Commerce.
Mar 23, 2017
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action March 24, 2017

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Medical Product Communications Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to state that the intended use of a drug, biological product, or device shall be determined by the objective intent of the manufacturer and sponsor of such drug, biological product, or device, as demonstrated by statements contained in labeling, advertising, or analogous oral statements.

The intended use of these medical products shall not be determined by actual or constructive knowledge of the manufacturer or sponsor that these products will be used in a manner that varies from the use approved for marketing.

Additionally, the scientific exchange of information about these products shall not constitute labeling, advertising, or evidence of a new intended use. The bill sets forth the requirements for a scientific exchange.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Republican 1
R
Bilirakis, Gus M.
Florida · Jun 2, 2017
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1703: Medical Product Communications Act of 2017. 115th Congress. Open America. https://openamerica.io/bill/115-HR-1703/
MLA
"H.R. 1703: Medical Product Communications Act of 2017." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-1703/.
Bluebook (legal)
H.R. 1703, 115th Cong. (2026), https://openamerica.io/bill/115-HR-1703/.
Markdown link
[H.R. 1703: Medical Product Communications Act of 2017](https://openamerica.io/bill/115-HR-1703/)
Report a problem